API Material Bivalirudin Trifluoroacetate CAS 128270-60-0 Bivalirudin Powder

API Material Bivalirudin Trifluoroacetate CAS 128270-60-0 Bivalirudin Powder

What is Bivalirudin Trifluoroacetate?

Bivalirudin, also known as Bivalirudin Trifluoroacetate, is a synthetic peptide drug used as an anticoagulant in medical settings. With a molecular weight of 2180 Daltons, it is a direct thrombin inhibitor that works by binding to both circulating and clot-bound thrombin, preventing the conversion of fibrinogen to fibrin and thus inhibiting blood clot formation.

Bivalirudin Benefits

Bivalirudin has a inhibitory effect on soluble and thrombus-bound thrombin in vitro. That effect cannot be affected by products that are released by platelet, and it can extend plasma activated partial thromboplastin time, thrombin time and prothrombin time of normal human with a dose-dependent manner. It is suitable for percutaneous coronary intervention (PCI) unstable angina.

Clinically experiments prove that bivalirudin is more effective than the current mainstream unfractionated heparin/low molecular weight heparin and platelet glycoprotein receptor antagonist in applications around PCI. Especially the risk of bleeding has a significant reduction, and the use safety of anticoagulants is greatly improved: 
1. It can significantly reduce the incidence of bleeding in elective PCI patients. The total clinical outcome risk fell 14%.
2. It does not cause antibody-mediated thrombocytopenia.
3. Reversibly bind with thrombin. Short half-life. Hard to develop ischemic and hemorrhagic complications. 
4. It is not mainly excreted through the kidneys and can be safely used in patients with renal impairment. 

Applicaton

Bivalirudin is highly effective in preventing blood coagulation and is primarily used during percutaneous coronary intervention (PCI) procedures, such as balloon angioplasty or stent placement, in patients with acute coronary syndromes. It is administered intravenously and is often combined with aspirin and/or other antiplatelet drugs to achieve optimal anticoagulation and ensure procedural success.

In terms of its efficacy, Bivalirudin has shown superiority over alternative anticoagulants in reducing the risk of major adverse cardiac events, including myocardial infarction and stent thrombosis, while maintaining a lower incidence of bleeding complications. This makes it a preferred option in patients with a high risk of bleeding or those undergoing complex interventions.

Company Information